Georgetown University Medical Center

Immunome Appoints Sandra M. Swain to Board of Directors

Retrieved on: 
木曜日, 4月 25, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, MedStar Health, University, Bangladesh Technical Education Board, Pfizer, Genetic distance, Professor, Vanderbilt University, Doctor of Philosophy, National Cancer Institute, Dean (education), IND, ASCO, Patient, National Institutes of Health, Society, Acquisition, Executive Committee, Georgetown University Medical Center, Internal medicine, Investigational New Drug

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors.

Key Points: 
  • Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors.
  • “Immunome is pleased to welcome Sandra to the Board of Directors, especially given her extensive experience as a successful clinical researcher,” stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.
  • Dr. Swain served on the board of directors of the American Society of Clinical Oncology (ASCO) from 2008-2013 and was ASCO President 2012-13.
  • Dr. Swain previously served on the board of directors of Seagen Inc. from November 2022 until its acquisition by Pfizer Inc. in December 2023.

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Retrieved on: 
木曜日, 3月 21, 2024
Visual Science, Uveitis, Wilmer Ophthalmological Institute, Brandeis University, Neurophysiology, NCP, BID, Telecanthus, Research, KOL, University, Patient, Doctor of Philosophy, Bascom Palmer Eye Institute, DED, Georgetown University Medical Center, Pain, Therapy, Johns Hopkins Hospital, Medical director, FDA, Pharmaceutical industry

LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be hosting a Key Opinion Leader (KOL) event on April 9th, 2024 at 12:00 PM ET to discuss in depth the findings of the new and comprehensive efficacy data readout from the Phase 2 trial of OK-101 in dry eye disease, which will be announced on March 22nd, 2024.

Key Points: 
  • OKYO Pharma’s management team will also be in attendance to present an overview of OK-101’s mechanism of action.
  • He has published over 200 peer-reviewed articles and has served on the editorial boards of several prestigious ophthalmology journals.
  • Additionally, statistically significant improvements were observed in both a “sign” (total conjunctival staining) and two “symptoms” (burning/stinging and blurred vision), which are FDA-recognized endpoints of dry eye disease.
  • The double-masked, randomized, placebo-controlled Phase 2 trial was conducted at six sites in the U.S. and enrolled 240 subjects with DED dosed twice-daily (BID).

The Washington, D.C. Auto Show, the Washington Area Hyundai Dealers and Hyundai Hope on Wheels Team up to Support Georgetown Lombardi and Children’s National Hospital Through “Hyundai Hands On Hope” Contest

Retrieved on: 
水曜日, 1月 17, 2024
Research, Cancer, NCI, Young adult, National Cancer Institute, Walter, Washington Convention Center, Diagnosis, Adolescence, Hope, Hackensack Meridian Health, L Street Bridge, Hyundai Motor America, Washington Auto Show, Georgetown University Medical Center, MedStar Health, Health, Hyundai, Child, Hospital, Human, Ewing sarcoma, Contest, Partnership, News, Nursing, Clinical trial, Automotive industry

Drawing inspiration from Hyundai Hope on Wheels, the new contest was named “Hyundai Hands On Hope.”

Key Points: 
  • Drawing inspiration from Hyundai Hope on Wheels, the new contest was named “Hyundai Hands On Hope.”
    Six contestants will compete for a brand-new 2024 Hyundai IONIQ6 over the 44-hour contest period.
  • “Every 36 minutes a child is diagnosed with pediatric cancer” shared Kevin Reilly, President of The Washington Area Hyundai Dealers, and Vice Chair of Hyundai Hope on Wheels.
  • In 2023, Hyundai Hope on Wheels celebrated its 25th Anniversary since inception, donating over $225 million in pediatric cancer research grants.
  • A part of Georgetown University Medical Center, Georgetown Lombardi is the only comprehensive cancer center in the Washington, D.C., area.

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Retrieved on: 
木曜日, 1月 4, 2024
Giant, Melanoma, Werewolf, Book, Immunotherapy, SITC, Kidney cancer, Society, Therapy, Biopharmaceutical, Georgetown University Medical Center, Harvard Medical School, Committee, Pharmaceutical industry

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.

Key Points: 
  • WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of novel, conditionally activated INDUKINE™ therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Michael B. Atkins, M.D., to its Board of Directors.
  • “Mike is a world-renowned oncologist and clinical researcher who has made countless contributions to the field of cancer immunotherapy.
  • I am delighted to have Mike join our Board at this important time in the clinical development of our WTX-124 and WTX-330 INDUKINE molecules,” said Dan Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics.
  • He has published over 500 scientific and review articles, co-edited five books, and given over 800 lectures worldwide.

Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP

Retrieved on: 
水曜日, 12月 13, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, PPCB, Lung, PRP, Pancreatic cancer, Prostate, Breast, Brain, Skin, OTC Markets Group, US Foods, Liver, Trypsinogen, Patient, Kidney, Neoplasm, Interview, MB, MD, Cancer, Georgetown University Medical Center, Survival, Growth, Chymotrypsinogen, Pharmaceutical industry

Research by this team of scientists, led by Professor Elisa Giovanetti, focuses on chemotherapy resistance in pancreatic cancer.

Key Points: 
  • Research by this team of scientists, led by Professor Elisa Giovanetti, focuses on chemotherapy resistance in pancreatic cancer.
  • “Chemotherapy is still considered an irreplaceable front-line therapeutic strategy to treat cancer.
  • But multidrug resistance represents a common hurdle that profoundly compromises clinical outcomes, especially in pancreatic cancer.
  • Tumor resistance to frontline chemotherapy means a poor prognosis for survival, especially in pancreatic cancer.

Octapharma AG: Indirect comparison data indicate that personalised prophylaxis with Nuwiq® may lead to fewer patients with haemophilia A having bleeds than with other recombinant factor VIII products

Retrieved on: 
火曜日, 10月 31, 2023
Haemophilia, Factor VIII, European Journal, PROPEL, PROTECT, Exercise, Georgetown University Medical Center, VIII, Georgetown Lombardi Comprehensive Cancer Center, Efmoroctocog alfa, Patient, Pharmaceutical industry, Dentistry

The analysis used data from prospective clinical trials of personalised prophylaxis in adults with severe haemophilia A.

Key Points: 
  • The analysis used data from prospective clinical trials of personalised prophylaxis in adults with severe haemophilia A.
    Dr Kessler commented, "This MAIC exercise provides important comparative data on the efficacy and consumption of various recombinant FVIII products in adults with haemophilia A on personalised prophylaxis.
  • The results can be considered by clinicians and patients when treatment decisions are being made."
  • MAICs are a way of comparing the efficacy of different medical interventions or products in the absence of head-to-head randomised trials3.
  • In addition, a short video summarising the results is available in the online version of the article.

Latest study demonstrates high efficacy in curing invasive non-melanoma skin cancer

Retrieved on: 
水曜日, 10月 25, 2023
Neoplasm, Patient, Cutaneous squamous-cell carcinoma, Incidence, NMSC, Georgetown University Medical Center, BCC, University Medical Center, Head, Face, Basal-cell carcinoma, CSCC, Cryotherapy, Carcinoma, Cancer, Radiation, Ear, Rhenium, Safety, Skin cancer, Hypopigmentation, Nose, Dentistry, Pharmaceutical industry, Veterinary medicine

MUNICH, Oct. 25, 2023 /PRNewswire/ -- Results from a recently completed study show topical rhenium-188 skin cancer therapy to be a highly effective option for treating non-melanoma skin cancer (NMSC) of up to 3 mm thickness.1

Key Points: 
  • Research lead, Professor Tietze from the University Medical Center, Rostock says, "The study found rhenium skin cancer therapy to be a highly effective treatment for NMSCs, in particular, the cosmetic outcomes on the head and face.
  • The study involved 22 patients with 40 histologically confirmed NMSCs (57.5% basal cell carcinomas (BCCs), 12.5% cutaneous squamous cell carcinomas (cSCCs), 30% Bowen's disease lesions).
  • This study shows the efficacy of rhenium skin cancer therapy demonstrating a 97.5% response rate with 37 of the 39 lesions showing complete response at 12 months," adds Professor Tietze.
  • All procedures performed in this study were in accordance with the 1964 Helsinki declaration and its later amendments.

EQS-News: AATec Medical GmbH: AATec Medical Announces Creation of Scientific Advisory Board

Retrieved on: 
火曜日, 10月 17, 2023
Health, GS, Georgetown University Medical Center, Viral, International Society, University Medical Center, Technical University of Munich, Leibniz-Institute of Virology, Institute of technology, Coronavirus Scientific Advisory Board, EMA, Asthma, Aerosol, Acute respiratory distress syndrome, Nature Communications, AAT, Research, ISAM, Pharmaceutical industry, Vaccine, Virology, Inam-ul-Haq (diplomat), Medicine

Leading scientific and clinical experts, Prof. Dr. Ulrike Protzer, Prof. Dr. Jan Münch, and Dr. Gerhard Scheuch, join the newly established Scientific Advisory Board

Key Points: 
  • Leading scientific and clinical experts, Prof. Dr. Ulrike Protzer, Prof. Dr. Jan Münch, and Dr. Gerhard Scheuch, join the newly established Scientific Advisory Board
    Munich, Germany – 10 October 2023 – AATec Medical GmbH (AATec), a biotech company developing a multi-product platform based on recombinant alpha-1 antitrypsin (AAT), today announced the creation of a Scientific Advisory Board.
  • Dr. Rüdiger Jankowsky, CEO commented: "We are honored to have such esteemed scientific experts joining AATec as advisors.
  • Our Scientific Advisory Board is composed of pioneers in the fields of respiratory diseases, viral infections, and aerosolized drugs.
  • The creation of the Scientific Advisory Board underscores AATec's commitment to unlocking the therapeutic potential of AAT, a human serine protease inhibitor with broad anti-inflammatory and antiviral effects to treat respiratory inflammatory diseases.

Landmark Study Demonstrates Clinical Validation of Aiberry AI-Powered Mental Health Assessments

Retrieved on: 
火曜日, 10月 3, 2023
Software, Health, Mental Health, Artificial Intelligence, Data Management, Health Technology, Technology, Clinical Trials, Linda, Depression, University, Peer review, University of Texas at Austin, Parity, Patient, Georgetown University Medical Center, Risk, Mental, AI, Bias, Mental health, Nursing

Aiberry®, a leading AI-powered mental health assessment platform, has successfully completed a clinical validation study in collaboration with The University of Texas at Austin.

Key Points: 
  • Aiberry®, a leading AI-powered mental health assessment platform, has successfully completed a clinical validation study in collaboration with The University of Texas at Austin.
  • Aiberry's distinctive, multi-modal approach evaluates an individual's mental health by analyzing text, audio, and video cues during a bot-administered interview.
  • “The US could double its number of mental health professionals overnight and still have a severe provider shortage,” said Lynne Dunbrack, Group Vice President for IDC Health Insights.
  • Overall, 88% of all respondents—regardless of depression severity—expressed a desire to use Aiberry at least monthly for mental health monitoring.

Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
月曜日, 8月 7, 2023
Duke University Hospital, Drug development, Boston University Chobanian & Avedisian School of Medicine, Microbiology, Pharmacia, Doctor of Philosophy, Crizotinib, Clinical trial, CMO, Boston University School of Public Health, Patient, Georgetown University Medical Center, SAN, Internal medicine, Cell, Sanofi, Jazz Pharmaceuticals, Bone marrow, Therapy, EBV, Pharmaceutical industry, Medicine, Pfizer

SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer (CMO), effective immediately.

Key Points: 
  • SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer (CMO), effective immediately.
  • Dr. Cohen will oversee the clinical development and regulatory advancement of Nana-val in Epstein-Barr virus (EBV)-associated malignances, contribute to the strategic expansion of Viracta’s pipeline, and serve on the Executive Leadership Team.
  • Prior to this, Dr. Cohen was CMO at Biosight Pharmaceuticals and Head of Clinical Development at EUSA Pharma.
  • and Ph.D. degrees in Medicine and Microbiology from Boston University School of Medicine, trained as a resident in Internal Medicine at Georgetown University Medical Center, and completed a fellowship in hematology/oncology at Duke University Medical Center.